Gland Pharma Ltd IPO

Gland Pharma Ltd, the Hyderabad-based company is one of the fastest-growing generic injectable companies. It manufactures a diversified range of high-quality complex injectables. The company offers products like sterile injectables, oncology, and ophthalmics, complex injectables (peptides, suspensions, hormonal products, long-acting injectables), NCE-1s, First-to-File products, etc.

The company follows a B2B model to sell its products in more than 60 countries including the US, Canada, Australia, India, Europe, etc. Leading pharma companies i.e. Sagent Pharmaceuticals, Apotex Inc. Athnex Pharmaceutical Division, LLC, Fresenius Kabi USA, LLC, etc. are some of the key customers.
It has 7 robust manufacturing units in India comprising 4 finished formulations facilities, 22 production lines, and 3 APIs.

Company Strengths:

The extensive product portfolio of complex injectables.
Diversified B2B model with a targeted B2C model in India.
Strong manufacturing capabilities.
Robust financial track record.
Experienced and qualified managerial team.

Company Promoters:

Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters.

Company Financials

Particulars	For the year/period ended (₹ in Million)
Summary of financial Information (Restated)	31-Mar-20	31-Mar-19	31-Mar-18
Total Assets	40,860.39	35,235.49	29,294.68
Total Revenue	27,274.08	21,297.67	16,716.82
Profit After Tax	7,728.58	4,518.56	3,210.51

Objects of the Issue:

The net proceeds from the IPO will be used for the following purposes:

1. To finance the incremental working capital requirements of our Company
2. To meet funding requirements for capital expenditure requirements
3. To meet the general corporate purposes

(Read Detailed Report)